Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote Sells 8,951 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 8,951 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $19.78, for a total transaction of $177,050.78. Following the completion of the transaction, the senior vice president now directly owns 95,719 shares in the company, valued at $1,893,321.82. This trade represents a 8.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Travere Therapeutics Trading Up 4.4 %

TVTX stock opened at $21.10 on Wednesday. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $21.56. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The company has a fifty day moving average of $18.69 and a 200-day moving average of $15.47.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Wedbush increased their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research report on Wednesday, October 9th. Bank of America increased their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright increased their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Piper Sandler increased their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. Finally, Scotiabank raised their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $24.00.

Institutional Trading of Travere Therapeutics

Several hedge funds have recently made changes to their positions in the company. Sei Investments Co. purchased a new stake in Travere Therapeutics during the second quarter worth about $117,000. Bank of Montreal Can purchased a new stake in Travere Therapeutics during the second quarter worth about $625,000. AQR Capital Management LLC boosted its holdings in Travere Therapeutics by 55.7% during the second quarter. AQR Capital Management LLC now owns 74,069 shares of the company’s stock worth $609,000 after buying an additional 26,485 shares in the last quarter. Diversified Trust Co purchased a new stake in Travere Therapeutics during the third quarter worth about $161,000. Finally, CWM LLC boosted its holdings in Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.